Article
Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy.
Atherosclerosis - 1 Mar 1995
Ordovas J M, Lopez-Miranda J, Perez-Jimenez F, Rodriguez C, Park J S, Cole T, Schaefer E J
Abstract excerpt
Our purpose was to assess the effect of apolipoprotein (apo) E and apo A-IV isoform variation on low density lipoprotein (LDL) cholesterol lowering response to the HMG CoA reductase inhibitor, pravastatin. Plasma samples were obtained from participants (apo E, n = 97; apo A-IV, n = 144) in the PL...
Topics
- Alleles
- Apolipoproteins A
- Apolipoproteins E
- Double-Blind Method
- Female
- Heterozygote
- Homozygote
- Humans
- Hydroxymethylglutaryl CoA Reductases
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Hyperlipoproteinemia Type II
- Lipoproteins, LDL
- Male
- Middle Aged
